Sofinnova Raises €333m For European Biotech Fund
Venture Capital Firm’s Funds Worth €2bn
Global investors back Paris-headquartered Sofinnova to recoup investment in life science start-ups.
You may also be interested in...
A new life sciences fund, LSP 6, is one of the largest fundraisings in Europe in the sector, and will invest in around 15-to-18 pharma or medtech companies.
Italy’s privately held Zambon could pay up to €500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.
In this tale of two companies, it's the best of times and the best of times. J&J gets immediate value by acquiring Actelion's blockbuster PAH franchise and its late-stage pipeline, while its stake in an Actelion spinout offers longer-term potential.